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E-mail address: szabo.gyula@med.u-szeged.hu (G.The aim of the present investigation was to study the effects of pituitary adenylate cyclase-activating
polypeptide (PACAP) on morphine withdrawal-induced behavioral changes and hypothermia in male
CFLP mice. Elevated plus maze (EPM) and jump tests were used to assess naloxone-precipitated mor-
phine withdrawal-induced behavior responses. Different doses of subcutaneous (s.c.) naloxone, (0.1
and 0.2 mg/kg, respectively) were used to precipitate the emotional and psychical aspects of withdrawal
on EPM and 1 mg/kg (s.c.) was used to induce the somatic withdrawal signs such as jumping, and the
changes in body temperature. In our EPM studies, naloxone proved to be anxiolytic in mice treated with
morphine. Chronic intracerebroventricular (i.c.v.) administration of PACAP alone had no signiﬁcant effect
on withdrawal-induced anxiolysis and total activity at doses of 500 ng and 1 lg. At dose of 500 ng, how-
ever, PACAP signiﬁcantly counteracted the reduced motor activity in the EPM test in mice treated with
morphine and diminished the hypothermia and shortened jump latency induced by naloxone in mice
treated with morphine.
These ﬁndings indicate that anxiolytic-like behavior may be mediated via a PACAP-involved pathway
and PACAP may play an important role in chronic morphine withdrawal-induced hypothermia as well.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
Pituitary adenylate cyclase-activating polypeptide (PACAP) was
originally isolated from ovine hypothalamus by its potent activity
in stimulating cAMP production in rat anterior pituitary cells
(Arimura, 1992). PACAP is a neuropeptide and member of a vasoac-
tive intestinal polypeptide (VIP) superfamily that includes several
peptides (VIP, secretin, helodermin, glucagon, peptide histidin
isoleucine, galanin, etc.) (Christophe, 1993; Gourlet et al., 1998).
The peptide has two amidated forms: PACAP-38 and PACAP-27
(Miyata et al., 1990). The presence of PACAP has been detected in
hypothalamus,medial andventral areas of thediencephalon, central
thalamic nuclei, amygdala, bed nucleus of stria terminalis, septum,
hippocampus, cingulate and entorhinal cortex, substantia nigra,
nucleus accumbens, globus pallidus and sacral spinal cord (Dietl
et al., 1990; Joo et al., 2004). Two receptor classes have been
described for PACAP in mammalian tissues: type I and type II. Typell rights reserved.
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Szabó).II was further divided into three subclasses: PAC1, VPAC1 and
VPAC2. PAC1 receptors are more selective for PACAP than VIP, but
VPAC1 and VPAC2 receptors show similar afﬁnity for PACAP-27,
PACAP-38 and VIP (Cauvin et al., 1990; Gourlet et al., 1996). Type I
receptors stimulate both adenylate cyclase and phospholipase C,
thus being coupled to dual transduction pathways, involving
interactions with G proteins of both Gs- and Gq-type. PACAP-38
and PACAP-27 were also effective in increasing cAMP release, cellu-
lar cAMP content, and total cAMP production in a dose-dependent
manner in common carp pituitary cells (Xiao et al., 2002) and in
rat neuroepithelial cells (Zhou et al., 2001).
Other behavioral studies examined the PACAP effect on motor
stimulation and conditioned place preference (CPP) induced by
morphine (Marquez et al., 2009); analgesic tolerance to morphine
(Mácsai et al., 2002); mechanical hyperalgesia and thermal allo-
dynia (Sándor et al., 2010). Our earlier experiments demonstrated
that PACAP diminished the antinociceptive effect of acute mor-
phine and enhanced the analgesic tolerance to morphine (Mácsai
et al., 2002). In a recent report, acute PACAP administration
increased the amount of time that animals spent in the open
arm/total time rate in morphine treated mice compared to mor-
phine treated mice in the absence of PACAP in the EPM (Szakács
12 N. Lipták et al. / Neuropeptides 46 (2012) 11–17et al., 2010). Low doses of PACAP (0.03 and 0.3 lg), which had no
effect on basal motor activity, enhanced morphine-induced
(5 mg/kg, s.c.) motor stimulation and PACAP-deﬁcient mice exhib-
ited reduced morphine-induced motor stimulation (Marquez et al.,
2009). Morphine-induced CPP following a single alternate-day
saline/morphine (10 mg/kg, s.c.) conditioning was blunted in
PACAP-deﬁcient mice compared to their wild type littermates
(Marquez et al., 2009). In spite of intense research, the mechanisms
of PACAP action on morphine withdrawal-induced behavior
responses and motor activity changes have not been clariﬁed yet.
The goal of the present study was to examine the effects of PACAP
on naloxone precipitated morphine withdrawal in two experimen-
tal paradigms.Fig. 1. Assessment of naloxone-precipitated withdrawal jumping in mice treated
with graded doses of morphine. Graded doses of morphine (mg/kg, s.c. per
injection) or saline were given twice daily for 5 days (day 1, 20; day 2, 40; day 3, 60;
day 4, 80). Mice were also treated once a day with either PACAP (500 ng/2 ll) or
aCSF i.c.v. 30 min after morphine injection. On day 5, 30 min prior to test either
PACAP or aCSF was injected. Naloxone (1 mg/kg, s.c.) or saline was administered 2 h
after the ﬁnal injection of morphine at a dose of 100 mg/kg, and the jump latency
was immediately measured. Therefore, we injected morphine or saline 2 h; PACAP
or aCSF 30 min; naloxone or saline 0 min prior to jumping behavior. Number of
mice: control: 9, morphine withdrawal mice: 10, morphine withdrawal mice + PA-
CAP: 9, mice treated with PACAP: 9. Bars represent the latency of jump, vertical
lines on the top of the bars denote S.E.M., ⁄p < 0.05 vs. mice given morphine and
naloxone.2. Materials and methods
2.1. Animals
Male CFLP white mice (30 ± 5 g of weight) of an outbred strain
(Domaszék, Hungary) were used. They were kept under a standard
light–dark cycle (lights on between 07.00 and 19.00 h) with food
and water available ad libitum. The animals were kept and treated
according to the rules of the Ethical Committee for the Protection
of Animals in Research (Faculty of Medicine, University of Szeged,
Hungary).
2.2. Surgery
For intracerebroventricular (i.c.v.) cannulation, the mice were
anesthetized with intraperitoneal (i.p.) injection of sodium pento-
barbital (Nembutal, Phylaxia-Sanoﬁ, Budapest, Hungary; 50 mg/
kg), and a polyethylene cannula was inserted into the right lateral
cerebral ventricle and cemented to the skull with cyanoacrylate-
containing instant glue. The experiments were started 4 days after
i.c.v. cannulation. Upon conclusion of the experiments, 10 ll of
methylene blue were injected into the cerebral ventricle of the
decapitated animals and the position of the cannula was inspected
visually. After injection methylene blue spread throughout the
ventricular space was used to verify that the whole amount of PA-
CAP got into the ventricle. Mice with improper cannula placement
were excluded from the statistical analysis.
2.3. Drugs
For i.c.v. treatments PACAP-38 (synthesized by Gábor Tóth
using solid-phase peptide synthesis) were dissolved in artiﬁcial
cerebrospinal ﬂuid (aCSF) and injected in a volume of 2 ll. For test-
ing the morphine effects and the somatic signs of withdrawal, mor-
phine–HCl (Sigma–Aldrich) and naloxone–HCl (Sigma–Aldrich)
were used. Control mice received saline s.c. and aCSF i.c.v.
2.4. Assessment of naloxone-precipitated withdrawal jumping in mice
treated with graded doses of morphine
Precipitated withdrawal jump latency was measured in mice
treated with morphine in the presence and absence of PACAP after
naloxone (1 mg/kg, s.c.) administration. Immediately after the nal-
oxone or saline injection, mice were placed on a circular platform.
The precipitated abstinence syndrome was measured by scoring
the latency to the appearance of stereotyped jumping from a circu-
lar platform 35 cm in diameter and 70 cm high (Azarov et al.,
1992). A cutoff time of 15 min was used. The rectal body temper-
atures and body weights of all animals were also measured 15,
30, 60 min after naloxone injection, and changes in both parame-
ters were calculated.2.4.1. Inﬂuence of PACAP on naloxone-precipitated morphine
withdrawal symptoms
We used twice daily injections of graded doses of morphine
(09.00 and 19.00 h.) as follows: day 1: 20 mg/kg, day 2: 40 mg/kg,
day 3: 60 mg/kg, day 4: 80 mg/kg or saline (Contet et al., 2008).
Mice were also treated once a day (09.30 h) with either PACAP
(500 ng/2 ll) or aCSF i.c.v. On the test day (day 5) animals received
in the morning a single morphine injection (100 mg/kg s.c., 9.00 h)
or saline (s.c.). Ninety minutes later aCSF or PACAP was given
(10.30 h, i.c.v.). Withdrawal signs were evoked by naloxone admin-
istration (1 mg/kg, s.c.) 2 h after the ﬁnal morphine treatment.
Precipitated morphine withdrawal syndrome was induced by
1 mg/kg naloxone-HCl as described by Azarov et al. (1992)). For
treatment of speciﬁc groups please see legends to ﬁgures (Figs. 1
and 2) and Table 1.2.5. Elevated plus maze (EPM)
The elevated plus maze (EPM) is an accepted model for examin-
ing anxiety-like behavior in mice (Lister, 1987). Conditions that de-
crease time spent in the open arms are associated with anxiety-like
behavior, whereas increased time spent in the open arms is associ-
ated with an anxiolytic effect. The EPM apparatus consists of four
arms (87-mm wide, 155-mm long) elevated 63.8 cm above the
ground, with two arms enclosed by 16.3-cm-high opaque walls
and illuminated with 60W light situated 1 m above the maze.
The combination of height, luminosity and open space is assumed
to induce anxiety-like behavior in the animal. Behavioral testing
was conducted between 11.00 and 13.00 h. Mice were carried to
the experimental room in their home cages and habituated to
the laboratory for at least 30 min before testing. Only one EPM
apparatus per testing room was present. The apparatus was thor-
oughly cleaned between mice. Mice were placed in the center of
the maze facing toward an enclosed arm and there behavioral
activity were recorded for 10 min (Schulteis et al., 1998). These
behavioral parameters were monitored: duration of time spent in
the open arms which was deﬁned as all four legs having crossed
the entrance line to one of the open arms and total activity which
was deﬁned as the total number of crosses between any two arms.
Fig. 2. The effect of PACAP on hypothermia induced by naloxone in mice treated with morphine. Treatment protocol and the number of mice were the same as naloxone-
precipitated withdrawal jumping experiment. The body temperatures of all animals were measured 15, 30, 60 min after naloxone injection. Bars represent the decreasing of
body temperature, vertical lines on the top of the bars denote S.E.M., ⁄p < 0.05 vs. mice given morphine and naloxone.
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Mice were treated once a day (09.30 h) with either PACAP
(500 ng or 1 lg i.c.v.) or aCSF for 3 consecutive days. On the test
day (day 4) PACAP or aCSF was administered 30 min before EPM
assessment. The parameters were monitored as mentioned above.2.5.2. The effect of naloxone on EPM behavior in mice treated with
morphine in the absence of PACAP
We used twice daily injections of graded doses of morphine
(09.00 and 17.00 h.) as follows: day 1: 10 mg/kg, day 2: 20 mg/
kg, day 3: 40 mg/kg or saline (Hodgson et al., 2008).
On the test day (day 4) animals received a single dose of mor-
phine (20 mg/kg, s.c.) or saline (s.c.) in the morning at 09.00 h. Nal-
oxone treatment in a dose of 0.1 mg/kg, or 0.2 mg/kg, s.c. preceded
behavioral assessment by 5 min. The behavioral changes were
measured 2 h after the ﬁnal morphine treatment with EPM test
(Higgins and Sellers, 1994; Schulteis et al., 1994). The treatment
of speciﬁc groups is described below Fig. 3 and on Table 2.2.5.2.1. The effect of naloxone on EPM behavior in mice treated with
morphine in the presence of PACAP. A previous study carried out in
our laboratory used once daily i.c.v. injection of PACAP (Mácsai
et al., 2002). Repeated administration of PACAP (500 ng/2 ll) sig-
niﬁcantly increased the chronic tolerance to morphine and en-
hanced the naloxone-precipitated withdrawal jumping. The aim
of that experiment model was to examine the somatic signs of
morphine tolerance and withdrawal after naloxone administration.
There is another study which described increased EPM open-arm
time in mice during naloxone-precipitated morphine withdrawal
(Hodgson et al., 2008). We combined these two protocols to exam-
ine the effect of PACAP on EPM behavior during naloxone-precipi-
tated morphine withdrawal.
Morphine administration regimen was the same as in the previ-
ous experiment. In addition, mice were treated once a day with
either PACAP (500 ng/2 ll) or aCSF (i.c.v.) at 09.30 h. On the test
day (day 4) animals received the ﬁnal morphine dose (20 mg/kg
s.c.), or saline (s.c.).
9.00 h and either aCSF or PACAP (i.c.v.) was given at 10.30 h.
Naloxone treatment and behavioral assessment were conducted
in the same way as outlined in the previous experiment with one
exception that only the higher dose of naloxone was used
(0.2 mg/kg, s.c.). For speciﬁc treatment groups and protocols please
see the legend to Figs. 4 and 5 and on Table 3.2.6. Statistical analysis
Statistical analysis of the data was made by one-way repeated
measure analysis of variance (ANOVA). For signiﬁcant ANOVA val-
ues, groups were compared by Tukey’s test for multiple compari-
sons with unequal cell size. A probability value, P < 0.05 was
considered statistically signiﬁcant.3. Results
3.1. Assessment of naloxone-precipitated withdrawal jumping in mice
treated with graded doses of morphine
Repeated treatment of PACAP shortened jump latency in mice
treated with morphine and challenged with naloxone [F(3,37) =
23.73, P < 0.023] (Fig. 1).
3.2. The effect of PACAP on hypothermia induced by naloxone in mice
treated with morphine
Fifteen minutes after naloxone treatment PACAP blunted
hypothermia induced by morphine withdrawal [F(3,37) = 32.97,
P < 0.034]. However, 30 and 60 min after withdrawal PACAP had
no signiﬁcant effect on body temperature (Fig. 2). PACAP treatment
alone did not inﬂuence the body weight of mice upon withdrawal
(data not shown).
3.3. The effects of PACAP on EPM behavior
Both doses of PACAP increased the open arm time/total time
rate, but no signiﬁcant difference was observed. There was a slight
increase upon the higher dose of PACAP compared to control mice
[F(2,27) = 3.63, P < 0.0614]. PACAP had no effect on total activity
(data not shown).
3.4. The effect of naloxone on EPM behavior in mice treated with
morphine in the presence or absence of PACAP
Naloxone (0.2 mg/kg, s.c.) administration in mice treated with
morphine signiﬁcantly increased the open-arm time/total time rate
compared to the control mice and mice treated with morphine
[F(3,42) = 3.97, P < 0.0146]. Naloxone also signiﬁcantly enhanced
the number of open arm entries/total entries rate compared to
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14 N. Lipták et al. / Neuropeptides 46 (2012) 11–17the control mice and mice receiving 0.1 mg/kg naloxone
[F(3,42) = 4.18, P < 0.0117]. Naloxone (0.1 mg/kg, s.c.) had no signiﬁ-
cant effect on withdrawal behavior compared to the mice treated
with morphine (Fig. 3).
In combination with PACAP (for treatment details see Table 3),
naloxone administration in mice treated with morphine again sig-
niﬁcantly increased the open-arm time/total time rate compared to
the control mice and mice treated with morphine [F(3,35) = 5.32,
P < 0.0037]. However, PACAP had no signiﬁcant effect on EPM com-
pared to morphine withdrawal group (Fig. 4).3.5. The effects of PACAP on motor activity in controls and mice treated
with morphine challenged with naloxone
Total motor activity was reduced in mice treated with mor-
phine, a response that was not altered in mice treated with nalox-
one. However, PACAP treatment blocked the reduction of total
activity induced by chronic morphine treatment [F(3,35) = 5.80,
P < 0.0026] (Fig. 5).4. Discussion
In this study we investigated the effect of PACAP on morphine
withdrawal-induced behavioral changes and hypothermia in mice.
A previous experiment demonstrated that PACAP (500 ng, i.c.v.)
signiﬁcantly diminished the analgesic effect of acute morphine in
mice (Mácsai et al., 2002). Morphine indirectly decreases the intra-
cellular level of cAMP due to inhibition of the enzyme adenylate
cyclase (Beitner et al., 1989; Kuriyama et al., 1978), but PACAP in-
creases the activity of adenylate cyclase, thus increasing the intra-
cellular level of cAMP (Absood et al., 1992). In contrast to the acute
morphine treatment, withdrawal from chronic morphine signiﬁ-
cantly upregulates the mRNA level of adenylate cyclase in the nu-
cleus raphe magnus, which causes an increase in cAMP level and
hyperalgesia (Bie et al., 2005).
PACAP alone caused hyperthermia in a dose dependent manner
in rat (Pataki et al., 2000) with 1000 ng induced the largest eleva-
tion in body temperature. The hyperthermic effect of PACAP may
be mediated via a cyclooxygenase-involved pathway, and it sug-
gest that PACAP may play an important role in thermoregulation
(Pataki et al., 2003). Morphine was able to induce both hyperther-
mia (through d- and j-opioid receptors) or hypothermia (through
l-opioid receptors) depending on the dose administrated, but nal-
oxone-precipitated morphine withdrawal evoked hypothermia
(Wang et al., 2008). In our study, we found that naloxone induced
hypothermia in mice treated with morphine was decreased by PA-
CAP (Fig. 2).
Chronic morphine withdrawal is known to be anxiogenic in hu-
mans and, using the EPM, was proved to be anxiogenic in rats as
well (Schulteis et al., 1998; Zhang and Schulteis, 2008). In contrast
to rats, both naloxone-precipitated (Hodgson et al., 2008), and
spontaneous opioid withdrawal (Buckman et al., 2009) exhibited
reduced anxiety-like behaviors on EPM in mice. In contrast to
EPM results, naloxone-precipitated morphine withdrawal caused
a rise in plasma and brain corticosterone levels (Budziszewska
et al., 1996; Hodgson et al., 2008; Kishioka et al., 1994; Rabbani
et al., 2009). Different doses of naloxone (0.1; 0.2 mg/kg) increased
EPM open-arm time during naloxone-precipitated morphine with-
drawal compared to control and mice treated with morphine
(Hodgson et al., 2008).
For EPM experiments, we respected the protocol of Hodgson
et al. (2008). Our aim was not to induce somatic signs of with-
drawal on the EPM experiments. Naloxone (0.2 mg/kg, s.c.) admin-
istration in mice treated with morphine signiﬁcantly increased the
open-arm time/total time rate compared to the control mice and
Fig. 3. The effect of naloxone on EPM behavior in mice treated with morphine in absence of PACAP. The graded doses of morphine (mg/kg, s.c. per injection) or saline were
given twice daily for 3 days (day 1, 10; day 2, 20; day 3, 40). On day 4, naloxone (0.1 and 0.2 mg/kg, respectively) or saline was administered 2 h after the ﬁnal injection of
morphine at a dose of 20 mg/kg, and the EPM behaviors were measured 5 min after naloxone injection. Therefore, we injected morphine or saline 2 h; naloxone or saline
5 min prior to EPM assessment. Number of mice: control: 12, mice treated with morphine: 10, morphine withdrawal mice (0.1 mg/kg): 8, morphine withdrawal mice (0.2 mg/
kg): 13. Bars represent the open-arm time/total time rate and the number of open arm entries/total entries rate, vertical lines on the top of the bars denote S.E.M., ⁄p < 0.05 vs.
control mice and mice treated with morphine.
Table 2
Treatment schedule to investigate the effect of naloxone on EPM behavior in mice treated with morphine in the absence of PACAP.
Day 1 Day 2 Day 3 Day 4
a.m. p.m. a.m. p.m. a.m. p.m. 09.00–10.55 h staggered 1 h and 55 min later staggered 10.55–13.00 h
1 Sal Sal Sal Sal Sal Sal Sal Sal
2 M 10 mg/kg M 10 mg/kg M 20 mg/kg M 20 mg/kg M 40 mg/kg M 40 mg/kg M 20 mg/kg Sal
3 M 10 mg/kg M 10 mg/kg M 20 mg/kg M 20 mg/kg M 40 mg/kg M 40 mg/kg M 20 mg/kg N 0.1 mg/kg
4 M 10 mg/kg M 10 mg/kg M 20 mg/kg M 20 mg/kg M 40 mg/kg M 40 mg/kg M 20 mg/kg N 0.2 mg/kg
Groups: 1: control mice, 2: mice treated with morphine, 3: morphine withdrawal mice (0.1 mg/kg naloxone), 4: morphine withdrawal mice (0.2 mg/kg naloxone).
M: morphine, N: naloxone, Sal: saline.
Fig. 4. The effect of naloxone on EPM behavior in mice treated with morphine in
the presence of PACAP. Morphine and naloxone treatments were the same as
outlined with Fig. 3. Mice were also treated once a day with either PACAP (500 ng/
2 ll) or aCSF i.c.v. 30 min after morphine injection for 3 days. On day 4, PACAP or
aCSF administrated 30 min prior to test. Accordingly, we injected morphine or
saline 2 h; PACAP or aCSF 30 min; naloxone or saline 5 min prior to EPM test.
Number of mice: control: 9, mice treated with morphine: 10, morphine withdrawal
mice: 10, morphine withdrawal mice + PACAP: 8. Bars represent the open-arm
time/total time rate, vertical lines on the top of the bars denote S.E.M., ⁄p < 0.05 vs.
control mice and mice treated with morphine.
Fig. 5. The effects of PACAP on motor activity in controls and mice treated with
morphine challenged with naloxone. Treatment protocol and the number of mice
were the same as outlined with Fig. 4. Bars represent the total activity, vertical lines
on the top of the bars denote S.E.M., ⁄p < 0.05 compared with mice treated with
morphine. PACAP signiﬁcantly increased the total activity vs. mice treated with
morphine. ⁄p < 0.05.
N. Lipták et al. / Neuropeptides 46 (2012) 11–17 15the mice treated with morphine. Moreover, naloxone signiﬁcantly
increased the number of open arm entries/total entries rate com-
pared with control mice and mice received 0.1 mg/kg naloxone
(Fig. 3). The 0.4 mg/kg dose of naloxone also increased theopen-arm time/total time rate, but mice fell off from the open
arm on every occasion (data not shown). There are no naloxone-
treated control groups in this study; because previous studies
proved that naloxone alone did not alter the behavior of mice on
the plus-maze apparatus (Hodgson et al., 2008; Ribeiro and De
Lima, 1998). In line with the literature, previous experiments done
by our research group also demonstrated that naloxone alone had
no effect on withdrawal jumping (Babarczy et al., 1996). We
Table 3
Treatment schedule to study the effect of naloxone on EPM behavior in mice treated with morphine in the presence of PACAP.
Day 1 Day 2 Day 3 Day 4
a.m. p.m. a.m. p.m. a.m. p.m. 09.00–10.55 h
staggered
1 h 30 min later staggered
10.30–12.30 h
1 h and 55 min later
staggered 10.55–13.00 h
1 Sal + aCSF Sal Sal + aCSF Sal Sal + aCSF Sal Sal aCSF Sal
2 M 10 mg/kg
and aCSF
M
10 mg/
kg
M 20 mg/kg
and aCSF
M
20 mg/
kg
M 40 mg/kg
and aCSF
M
40 mg/
kg
M 20 mg/kg aCSF Sal
3 M 10 mg/kg
and aCSF
M
10 mg/
kg
M 20 mg/kg
and aCSF
M
20 mg/
kg
M 40 mg/kg
and aCSF
M
40 mg/
kg
M 20 mg/kg aCSF N: 0.2 mg/kg
4 M 10 mg/kg
and PACAP
M
10 mg/
kg
M 20 mg/kg
and PACAP
M
20 mg/
kg
M 40 mg/kg
and PACAP
M
40 mg/
kg
M 20 mg/kg PACAP N: 0.2 mg/kg
Groups: 1: control mice, 2: mice treated with morphine, 3: morphine withdrawal mice, 4: morphine withdrawal mice receiving PACAP.
M: morphine, N: naloxone, Sal: saline, aCSF: artiﬁcial cerebrospinal ﬂuid.
16 N. Lipták et al. / Neuropeptides 46 (2012) 11–17examined the effect of chronic PACAP administration on naloxone-
induced morphine withdrawal behavior using EPM. In other exper-
iments, acute administration of PACAP at dose dependent manner
inﬂuenced morphine-induced locomotion: at lower doses (0.03
and 0.3 lg) increased, at higher dose inhibited (1 lg) morphine-in-
duced locomotion (Marquez et al., 2009). According to another
study, single i.c.v. doses of 500 ng and 1 lg PACAP had locomotor
stimulating effect in open ﬁeld test, 30 min post-treatment in rat
(Adamik and Telegdy, 2004). Therefore, in our experiments
30 min after last PACAP injection (500 ng) the EPM test was
started. After naloxone-precipitated withdrawal, mice treated with
PACAP and morphine showed a signiﬁcant increase in the total mo-
tor activity compared to the mice treated with morphine. Control
mice exhibited similar behavior (Fig. 5). This increased total activ-
ity may be regarded as escape or defensive behavior or decrease
feeling of fear (Hodgson et al., 2008). This phenomenon is perhaps
mediated by dopamine receptors in the amygdala (Rezayof et al.,
2009; Zhang and Schulteis, 2008), However, the role of dorsal peri-
aqueductal gray and inferior colliculus cannot be ruled out (Avila
et al., 2008; De et al., 2009). A recent study suggest that chronic
stress (footshock, forced swim, oscillation stress, etc.) increases PA-
CAP mRNA expression in the bed nucleus of the stria terminalis
and PACAP is anxiogenic (Hammack et al., 2009). We could not
conﬁrm these results; PACAP alone increased the open arm time/
total time rate and had no effect on total activity. Though the high-
er dose of PACAP has shown to be more effective than the lower
(500 ng) dose, its combination with chronically administered mor-
phine caused a marked increase in mortality of mice. Chronic PA-
CAP treatment did not inﬂuence signiﬁcantly the open arm time/
total time rate in mice undergoing naloxone-precipitated mor-
phine withdrawal. These results allude to anxiolytic effect of PA-
CAP, but differences were not signiﬁcant compared to aCSF
treated control mice (P < 0.0614).
Jump latency is an accepted method to report the somatic signs
of withdrawal (Babarczy et al., 1995a,b; Babarczy et al., 1996; Mill-
er et al., 1983). Mice chronically treated with PACAP and morphine
jumped off the platform earlier than mice treated with morphine
after withdrawal. Thus, PACAP enhanced this aversive effect of opi-
oid withdrawal (Fig. 1). A previous study carried out in our labora-
tory showed a similar result using morphine pellet implantation
(Mácsai et al., 2002). Although withdrawal jumping is a somatic
withdrawal symptom in mice and rats, perhaps this is the same es-
cape behavior, which we experienced on EPM tests.
In conclusion, our study demonstrated that PACAP could modify
several effect of morphine withdrawal in mice (e.g. total motor
activity), but enhanced other negative effects (e.g. latency to
jump). Based upon these experiments, it is difﬁcult to determine
whether PACAP exerted its effect on the expression or on theacquisition of morphine withdrawal. Earlier data showed that PA-
CAP played an important role in thermoregulation and enhanced
the chronic analgesic tolerance to morphine. Our data suggest that
naloxone-precipitated withdrawal did not evoke anxiety-like
behavior; rather, it induced anxiolytic effect in mice. PACAP was
able to lower total activity on EPM upon chronic morphine chal-
lenge. These data may also help us to better understand the mech-
anisms of morphine withdrawal-induced behavioral changes and
the physiological and pathological role of PACAP in different
behavior responses.5. Conﬂict of interest statement
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